Dexrazoxane is a cardioprotective drug used to reduce heart damage caused by anthracycline chemotherapy, which treats various cancers. In adults, evidence supports its ability to prevent or reduce clinical heart failure, with studies showing a significant reduction in cardiac damage risks. Importantly, dexrazoxane does not negatively affect overall survival (OS), progression-free survival (PFS), or tumor response rates in adults. For children, its benefits are less consistent. While one study indicated reduced cardiac risks, others showed no significant difference. However, concerns about an increased risk of secondary cancers in pediatric cases highlight the need for careful risk assessment and more high-quality research.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Home
